REZZAYO Drug Patent Profile

Which patents cover Rezzayo, and when can generic versions of Rezzayo launch?

Rezzayo is a drug marketed by Mundipharma and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and six patent family members in twenty-eight countries.

The generic ingredient in REZZAYO is rezafungin acetate. One supplier is listed for this compound. Additional details are available on the rezafungin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rezzayo

Rezzayo will be eligible for patent challenges on March 22, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 22, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for REZZAYO

International Patents:	106
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for REZZAYO
What excipients (inactive ingredients) are in REZZAYO?	REZZAYO excipients list
DailyMed Link:	REZZAYO at DailyMed

See drug prices for REZZAYO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for REZZAYO

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

217417

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for REZZAYO

Drug Class

Echinocandin Antifungal

US Patents and Regulatory Information for REZZAYO

REZZAYO is protected by seven US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	10,702,573		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	11,819,533		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	11,197,909		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	9,526,835		Y	Y
Mundipharma	REZZAYO	rezafungin acetate	POWDER;INTRAVENOUS	217417-001	Mar 22, 2023		RX	Yes	Yes	8,722,619		Y	Y

International Patents for REZZAYO

See the table below for patents covering REZZAYO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013235512
Australia	2017201758
Australia	2019201072
Australia	2020256337
Canada	2867132
China	104507309

Supplementary Protection Certificates for REZZAYO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2680873	301280	Netherlands		PRODUCT NAME: REZAFUNGIN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER REZAFUNGINACETAAT; REGISTRATION NO/DATE: EU/1/23/1775 20231222
2680873	CA 2024 00025	Denmark		PRODUCT NAME: REZAFUNGIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER REZAFUNGINACETAT; REG. NO/DATE: EU/1/23/1775 20231222
2680873	PA2024520	Lithuania		PRODUCT NAME: REZAFUNGINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC REZAFUNGINO ACETATAS; REGISTRATION NO/DATE: EU/1/23/1775 20231222
2680873	LUC00351	Luxembourg		PRODUCT NAME: REZAFUNGIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR REZAFUNGIN ACETATE; AUTHORISATION NUMBER AND DATE: EU/1/23/1775 20231222
2680873	2024C/527	Belgium		PRODUCT NAME: REZAFUNGINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER REZAFUNGINEACETAAT; AUTHORISATION NUMBER AND DATE: EU/1/23/1775 20231222
2680873	122024000037	Germany		PRODUCT NAME: REZAFUNGIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE REZAFUNGINACETAT; REGISTRATION NO/DATE: EU/1/23/1775 20231222

Last updated: July 30, 2026

REZZAYO (rezafungin) market dynamics and financial trajectory: sales, payer pull, and exclusivity-driven risk

REZZAYO (rezafungin) is an echinocandin antifungal positioned for invasive candidiasis and candidemia in adults, with launch momentum tied to hospital formularies and stewardship. Financial performance and market share have been shaped by (1) a late-cycle time to entry versus older echinocandins and (2) near-term replacement risk from price pressure and therapeutic switching as generic and branded alternatives compete on acquisition cost. The key forward-looking variable is uptake volume from high-acuity inpatient centers rather than outpatient demand.

What is REZZAYO (rezafungin) and where does it fit in the invasive candidiasis market?

REZZAYO is a once-weekly echinocandin administered for invasive candidiasis. In practice, its value proposition centers on convenience versus daily echinocandin dosing schedules, with hospital adoption dependent on IV workflow, nursing time, and line management. Uptake is also influenced by guideline alignment and formulary placement against caspofungin, micafungin, and anidulafungin.

How does rezafungin compare with the echinocandin standard of care?

• Standard comparator set: caspofungin, micafungin, anidulafungin (daily dosing).
• Differentiation: weekly dosing schedule (operational convenience in inpatient care).
• Adoption friction points: acquisition cost versus bundled cost of administration; institutional comfort with a newer agent; conversion dynamics from existing stocked therapies.

Where does uptake come from (hospital segment vs geography)?

• Primary demand drivers are tertiary hospitals, ICUs, and large ID centers that manage antifungal stewardship and high-volume candidemia caseloads.
• Penetration tends to be strongest in systems with antimicrobial programs that evaluate dosing schedules and pharmacy administration logistics.

What do sales dynamics look like after launch for REZZAYO?

REZZAYO’s sales trajectory is typically governed by three phases common to hospital-only antifungals:

1. Early adoption: uptake by ID-led centers that incorporate new guidance and evaluate workflow advantages.
2. Formulary tightening: as health systems standardize antifungals, continued growth depends on demonstrating net value beyond convenience, including day-of-therapy efficiency and favorable internal case mix.
3. Price and switching pressure: as competitors discount or expand access, price realization and therapy switching determine whether REZZAYO sustains volume or plateaus.

What are the key levers for REZZAYO revenue growth?

• Hospital formulary placement (national, regional, or group purchasing organization agreements).
• Payer contracting and reimbursement tied to inpatient drug budgets.
• Use as first-line vs switch therapy: adoption patterns can shift between empiric therapy and post-culture confirmation.
• Stewardship performance: confidence in clinical outcomes across broad hospital populations.

What limits growth for REZZAYO?

• Therapeutic conservatism in candidemia and complicated infections, where established agents already have institutional protocols.
• Procurement leverage: group purchasing organizations push pricing down and may favor preferred SKUs.
• Competing product economics: branded comparators face less uptake friction in systems with stable supply contracts.

When does REZZAYO face exclusivity pressure and how does it affect financial trajectory?

The financial arc for an originator hospital drug is tightly coupled to:

• regulatory exclusivity (data and marketing exclusivity where applicable),
• patent exclusivity (composition and method claims),
• and entry timing for generics or licensed competitors.

For REZZAYO, the exclusivity and patent landscape must be assessed claim-by-claim using Orange Book listings and related FDA documentation, because revenue risk is driven by:

• Paragraph IV generic challenges (if any are filed for relevant NDA approvals),
• patent settlements (if ANDA litigation occurs),
• and whether any compounding or non-labeled indications trigger off-label usage risk.

What patents protect REZZAYO and how many are likely in-force?

A complete and accurate protection map requires REZZAYO’s Orange Book patent list and associated FDA submission data (patent numbers, claim types, expiration dates, and regulatory exclusivity triggers). Under the constraints here, no Orange Book patent set for REZZAYO is provided, so the number and expiration schedule of protecting patents cannot be stated without risking inaccuracy.

What is the Orange Book status of REZZAYO (rezafungin)?

Orange Book status determines the practical exclusivity window for ANDA entry. The Orange Book dataset for REZZAYO is not included in the provided material, so a definitive “listed patents / expiration dates / exclusivity codes” status cannot be produced here.

How strong is the patent estate for REZZAYO versus generic and biosimilar risk?

Rezafungin is a small-molecule antifungal. That means generic risk follows the ANDA framework rather than biosimilar rules. The risk intensity depends on:

• whether composition-of-matter patents remain unexpired,
• whether formulation and method-of-use claims exist,
• and whether any granted patents are vulnerable to invalidation.

No in-force claim set is supplied here, so strength cannot be quantified.

What Paragraph IV challenges or ANDA filings affect REZZAYO’s growth outlook?

Paragraph IV filings and related district court actions can immediately shift market access via automatic stays (or the lack of them), settlement leverage, and payer contracting changes. No ANDA filing or Paragraph IV record for REZZAYO is provided here, so litigation-driven risk cannot be asserted.

What is the current competitive landscape for invasive candidiasis drugs like REZZAYO?

REZZAYO competes in a constrained but high-acuity segment where usage is guided by:

• clinical pathways for candidemia and invasive candidiasis,
• echinocandin class protocols,
• and hospital-specific antifungal formularies.

Who are the main competitors to REZZAYO in practice?

• Caspofungin (daily schedule)
• Micafungin (daily schedule)
• Anidulafungin (daily schedule)
• Additional antifungals can enter via salvage pathways (agent selection varies by resistance profiles and local stewardship protocols).

How does dosing convenience translate to spend management?

Weekly dosing can reduce:

• pharmacy preparation frequency,
• infusion administration encounters,
• and nursing time for line setup.

The commercial question is whether these operational savings outweigh acquisition cost differentials. If hospital systems already have efficient daily echinocandin workflows, REZZAYO’s incremental value may compress.

Which geographies and payer systems drive REZZAYO uptake?

Hospital drug uptake concentrates in:

• US inpatient systems with high antifungal use,
• integrated delivery networks with centralized pharmacy and procurement.

Payer dynamics matter less than contracting mechanics for hospital formularies. Commercial trajectory tends to be led by:

• group purchasing organization dynamics,
• and tiering within hospital drug budgets.

No sales-by-region data is included here, so geographic financial impact cannot be quantified.

How does REZZAYO compare financially to other injectable hospital antifungals?

A financial comparison requires:

• reported revenues and unit trends for rezafungin,
• comparable product revenue for echinocandins,
• and market-level pricing changes.

No REZZAYO revenue, unit, or price realization figures are supplied, so a numeric comparison cannot be produced.

What commercial events and manufacturing/IP barriers influence REZZAYO margins?

For hospital injectables, margin and scaling are influenced by:

• API and finished-dose supply stability,
• contract manufacturing utilization,
• temperature/handling constraints tied to IV drug logistics,
• and changes in access that affect volume.

No manufacturing capacity or COGS drivers for REZZAYO are provided here.

How do licensing deals and co-promotion agreements affect REZZAYO’s financial trajectory?

A drug’s market performance can hinge on:

• distribution footprint,
• commercialization cost structure,
• and incentive alignment.

No licensing or commercialization deal terms for REZZAYO are included here, so the effect on financial trajectory cannot be stated accurately.

What litigation or settlement agreements could change REZZAYO’s launch economics?

Patent litigation and settlements can reshape:

• timeline to competitor entry,
• payer formularies and preferred positioning,
• and manufacturer net pricing via competitive pressure.

No REZZAYO litigation or settlement documentation is provided here.

When are generic entry risks for REZZAYO highest under typical ANDA timelines?

Generic entry risk timing depends on:

• expiration of composition-of-matter patents,
• regulatory exclusivity expiration,
• and whether any patent is successfully challenged or design-around occurs.

No Orange Book patent expiration schedule for REZZAYO is supplied here, so no entry window can be calculated.

Key takeaways

• REZZAYO’s market dynamics are dominated by inpatient formulary adoption, stewardship protocols, and pricing pressure from established echinocandins.
• Financial trajectory is most sensitive to continued preferred status in large hospital systems and to payer and procurement contracting outcomes rather than outpatient demand.
• Exclusivity, patent coverage, and any Paragraph IV activity are the critical determinants of the next phase of revenue risk, but they cannot be mapped from the information provided here.

FAQs

1. Is rezafungin expected to capture first-line share in candidemia treatment or mainly switch therapy?
2. How do weekly dosing economics affect total cost of therapy versus daily echinocandins in hospital pharmacy models?
3. What contracting mechanisms (GPO formulary, bundled drug budgets) most influence REZZAYO net pricing?
4. What is the most common litigation pathway that would shorten REZZAYO’s exclusivity in the US?
5. How would a hypothetical competitor’s discounting strategy likely impact REZZAYO volume if formulary switching is permitted?

References (APA)

DrugChatter Q&A for REZZAYO

Evaluate the pharmaceuticals and biotechnology company mundipharma on rezzayo?
Rezzayo pharmaceuticals biotechnology company profile?
How many countries is rezzayo approved and sold to patients?